Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Alemtuzumab (compound)


PubChem Substance
Name: alemtuzumab
PubChem Substance ID: 17396960
Synonyms:
D02802; Alemtuzumab (USAN); Alemtuzumab; 216503-57-0; Campath (TN); Campath
DrugBank
Identification
Name: alemtuzumab
Name (isomeric): DB00087
Drug Type: biotech
Brand: MabCampath, Campath (ILEX Pharmaceuticals LP), Campath
Category: Antineoplastic Agents
CAS number: 216503-57-0
Pharmacology
Indication: Alemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia.
Pharmacology:
Campath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an exc...
show more »
Mechanism of Action: Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells.
Biotransformation: Most likely removed by opsonization via the reticuloendothelial system when bound to B or T lymphocytes
Half Life: ~288 hrs
Interactions
Drug interaction:
TrastuzumabTrastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.

Targets